Spots Global Cancer Trial Database for Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
Official Title: A Phase II Study to Evaluate the Efficacy, Safety, and Genomic Markers of Response of Capecitabine as NeoAdjuvant Therapy in Women With Newly Diagnosed Locally Advanced Breast Cancer
Study ID: NCT00347438
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and effectiveness of capecitabine before surgery. The study will also help gain more information about the effects of the capecitabine on physical and emotional well-being and how well the participants on capecitabine follow the study drug plan.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
University of Chicago, Chicago, Illinois, United States
University of Ibadan, Ibadan, , Nigeria
Obafemi Awolowo University, Ile-Ife, , Nigeria
Contact Details
Name: Olufunmilayo I Olopade, MD
Affiliation: University of Chicago
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
